CY1122385T1 - Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β - Google Patents

Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β

Info

Publication number
CY1122385T1
CY1122385T1 CY20191101067T CY191101067T CY1122385T1 CY 1122385 T1 CY1122385 T1 CY 1122385T1 CY 20191101067 T CY20191101067 T CY 20191101067T CY 191101067 T CY191101067 T CY 191101067T CY 1122385 T1 CY1122385 T1 CY 1122385T1
Authority
CY
Cyprus
Prior art keywords
tumor
selective
modified
adeno
mutants
Prior art date
Application number
CY20191101067T
Other languages
Greek (el)
English (en)
Inventor
Tony Reid
Farah Hedjran
Shantanu Kumar
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of CY1122385T1 publication Critical patent/CY1122385T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CY20191101067T 2009-03-02 2019-10-10 Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β CY1122385T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15682209P 2009-03-02 2009-03-02
EP10749205.0A EP2403951B1 (en) 2009-03-02 2010-03-02 Tumor-selective adenovirus e1a and e1b mutants
PCT/US2010/025926 WO2010101921A2 (en) 2009-03-02 2010-03-02 Tumor-selective e1a and e1b mutants

Publications (1)

Publication Number Publication Date
CY1122385T1 true CY1122385T1 (el) 2021-01-27

Family

ID=42710189

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101067T CY1122385T1 (el) 2009-03-02 2019-10-10 Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β

Country Status (15)

Country Link
US (6) US9073980B2 (enExample)
EP (4) EP2403951B1 (enExample)
JP (5) JP6072414B2 (enExample)
KR (4) KR101922539B1 (enExample)
CY (1) CY1122385T1 (enExample)
DK (2) DK3029144T3 (enExample)
ES (2) ES2557812T3 (enExample)
HR (2) HRP20151396T1 (enExample)
HU (2) HUE026386T2 (enExample)
LT (1) LT3029144T (enExample)
PL (2) PL3029144T3 (enExample)
PT (2) PT2403951E (enExample)
SI (2) SI2403951T1 (enExample)
SM (2) SMT201900565T1 (enExample)
WO (1) WO2010101921A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2403951E (pt) 2009-03-02 2016-01-29 Univ California Mutantes de adenovírus e1a e e1b de tumores
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CN111705116A (zh) 2013-07-19 2020-09-25 路德维格癌症研究有限公司 全基因组且靶向的单体型重构
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
EP3519442A4 (en) * 2016-09-27 2020-06-17 EpicentRx, Inc. Immunomodulatory fusion proteins
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
US20190352669A1 (en) * 2017-01-30 2019-11-21 Epicentrx, Inc. Tumor selective tata-box and caat-box mutants
SG11201906973TA (en) * 2017-01-30 2019-08-27 Epicentrx Inc Multiple transgene recombinant adenovirus
EP3610003A4 (en) * 2017-04-10 2021-01-06 EpicentRx, Inc. RECOMBINANT VIRUS PRODUCTION PROCESS
EA201990822A1 (ru) * 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
EP3630959A4 (en) * 2017-05-24 2021-03-17 EpicentRx, Inc. ANTI-ANGIOGENIC ADENOVIRUS
CN120796389A (zh) 2017-05-26 2025-10-17 埃皮森特Rx股份有限公司 携带转基因的重组腺病毒
IL273626B2 (en) 2017-09-27 2025-07-01 Epicentrx Inc Immunomodulatory fusion proteins
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
EP3773649A4 (en) 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
WO2020046130A1 (en) * 2018-08-31 2020-03-05 Orca Therapeutics B.V. Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (gsk3) and methods of killing aberrant cells
US20220403438A1 (en) 2019-10-08 2022-12-22 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
MX2022010936A (es) 2020-03-05 2022-11-16 Neotx Therapeutics Ltd ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas.
CN114262691A (zh) * 2020-09-16 2022-04-01 杭州康万达医药科技有限公司 分离的能够用于表达外源基因的溶瘤腺病毒、载体、治疗剂及其用途
EP4554559A1 (en) 2022-07-13 2025-05-21 EpicentRx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof
CN118931897A (zh) * 2024-06-27 2024-11-12 中山大学 一种识别肿瘤细胞并诱导其焦亡的基因、重组载体和重组病毒及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643567A (en) 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5352775A (en) 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
JPH06509578A (ja) 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
EP0694070B1 (en) 1993-09-15 2002-04-10 Chiron Corporation Recombinant alphavirus vectors
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US5902925A (en) 1996-07-01 1999-05-11 Integrated Sensor Solutions System and method for high accuracy calibration of a sensor for offset and sensitivity variation with temperature
GB9626029D0 (en) 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
US20050287120A1 (en) 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
AU772544B2 (en) * 1999-01-28 2004-04-29 Onyx Pharmaceuticals E1B-deleted adenoviral shuttle vectors
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
WO2001083797A2 (en) * 2000-04-28 2001-11-08 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
WO2002018550A1 (en) * 2000-08-25 2002-03-07 The General Hospital Corporation Selective precipitation of viruses
CN1183250C (zh) * 2000-12-01 2005-01-05 卫健生物科技有限公司 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法
GB0117198D0 (en) 2001-07-13 2001-09-05 Btg Int Ltd Anti-neoplastic viral agents
WO2004009768A2 (en) 2002-07-18 2004-01-29 Invitrogen Corporation Viral vectors containing recombination sites
WO2004020971A2 (en) * 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20060270016A1 (en) * 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
EP1830864A2 (de) * 2004-12-31 2007-09-12 Per Sonne Holm E1 -minus adenoviren und deren verwendung
KR101252065B1 (ko) * 2007-04-20 2013-04-12 다카라 바이오 가부시키가이샤 유전자 치료를 위한 벡터
PT2403951E (pt) 2009-03-02 2016-01-29 Univ California Mutantes de adenovírus e1a e e1b de tumores

Also Published As

Publication number Publication date
EP3591059B1 (en) 2022-07-20
DK3029144T3 (da) 2019-10-21
US11618888B2 (en) 2023-04-04
JP2012519014A (ja) 2012-08-23
EP4123030A1 (en) 2023-01-25
JP2016028035A (ja) 2016-02-25
KR20170077278A (ko) 2017-07-05
KR101922539B1 (ko) 2018-11-27
JP6072414B2 (ja) 2017-02-01
HUE026386T2 (en) 2016-06-28
EP3591059A1 (en) 2020-01-08
KR101752910B1 (ko) 2017-06-30
EP3029144B1 (en) 2019-07-10
PT2403951E (pt) 2016-01-29
SI2403951T1 (sl) 2016-04-29
US20210171917A1 (en) 2021-06-10
US20160017294A1 (en) 2016-01-21
JP2018113971A (ja) 2018-07-26
EP2403951B1 (en) 2015-09-30
PT3029144T (pt) 2019-10-28
SMT201500329B (it) 2016-02-25
US12195766B2 (en) 2025-01-14
US10876097B2 (en) 2020-12-29
DK2403951T3 (en) 2016-01-11
US20230272349A1 (en) 2023-08-31
KR20110122866A (ko) 2011-11-11
WO2010101921A2 (en) 2010-09-10
PL3029144T3 (pl) 2020-06-01
PL2403951T3 (pl) 2016-04-29
JP2022023074A (ja) 2022-02-07
EP2403951A4 (en) 2012-08-22
JP6375273B2 (ja) 2018-08-15
KR102150027B1 (ko) 2020-10-26
US9073980B2 (en) 2015-07-07
HRP20151396T1 (hr) 2016-03-25
HUE046565T2 (hu) 2020-03-30
HRP20191808T1 (hr) 2019-12-27
ES2750305T3 (es) 2020-03-25
JP7326396B2 (ja) 2023-08-15
US20110318311A1 (en) 2011-12-29
KR20180049188A (ko) 2018-05-10
SMT201900565T1 (it) 2019-11-13
JP6817979B2 (ja) 2021-01-20
JP2020078326A (ja) 2020-05-28
LT3029144T (lt) 2019-10-25
US20250327037A1 (en) 2025-10-23
WO2010101921A3 (en) 2011-01-06
EP2403951A2 (en) 2012-01-11
ES2557812T3 (es) 2016-01-28
EP3029144A1 (en) 2016-06-08
US20190136204A1 (en) 2019-05-09
SI3029144T1 (sl) 2019-11-29
KR20190104643A (ko) 2019-09-10
KR102020018B1 (ko) 2019-09-09

Similar Documents

Publication Publication Date Title
CY1122385T1 (el) Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β
CY1125475T1 (el) Χρηση οξυγονωμενης θειικης χοληστερολης (ocs) για την αντιμετωπιση της νεφρικης δυσλειτουργιας
IL268554A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP3890499A4 (en) Use of lactase to provide high gos fiber level and low lactose level
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
CL2016001507A1 (es) Compuestos para tratar pacientes con células cancerosas mutantes ros1
BR112019024813A2 (pt) adenovírus recombinantes portando transgenes
EP2139423A4 (en) SURGICAL PACKAGE AND BOWL
EP2558478A4 (en) AT 5 POSITIONS MODIFIED PYRIMIDINES AND THEIR USE
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
MY183703A (en) Oncolytic adenovirus encoding a b7 protein
EP2118123A4 (en) STABILIZED P53 PEPTIDES AND ITS USES
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
CY1110002T1 (el) Τροποποιημενη πρωτεϊνη ηεχον αδενοϊου και χρησεις αυτης
MX2013008375A (es) Anticuerpos anti proteina accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
DK3023788T3 (da) Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer
BR112015032690A8 (pt) uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases
MX388981B (es) Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
EP2424563A4 (en) CHIMERIC FACTOR H-BINDING PROTEINS AND METHOD OF USE THEREOF
NZ600974A (en) Binding members for human cytomegalovirus
BR112012001043A2 (pt) tinturas fluorescentes e uso das mesmas
BRPI0818766A2 (pt) N-fenil-pirrolidinilmetilpirrolidinamidas substituídas e uso terapêutico das mesmas
EP2170373A4 (en) THERMOSTABILIZATION OF PROTEINS
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna